Logo image of CBUS

CIBUS INC (CBUS) Stock Fundamental Analysis

NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD

1.44  -0.04 (-2.37%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CBUS. CBUS was compared to 551 industry peers in the Biotechnology industry. CBUS has a bad profitability rating. Also its financial health evaluation is rather negative. CBUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CBUS has reported negative net income.
CBUS had a negative operating cash flow in the past year.
In the past 5 years CBUS always reported negative net income.
In the past 5 years CBUS always reported negative operating cash flow.
CBUS Yearly Net Income VS EBIT VS OCF VS FCFCBUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of CBUS (-82.03%) is worse than 70.96% of its industry peers.
CBUS has a worse Return On Equity (-391.10%) than 74.77% of its industry peers.
Industry RankSector Rank
ROA -82.03%
ROE -391.1%
ROIC N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
CBUS Yearly ROA, ROE, ROICCBUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

CBUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBUS Yearly Profit, Operating, Gross MarginsCBUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CBUS has been increased compared to 1 year ago.
CBUS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CBUS has been reduced compared to a year ago.
CBUS Yearly Shares OutstandingCBUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CBUS Yearly Total Debt VS Total AssetsCBUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.83, we must say that CBUS is in the distress zone and has some risk of bankruptcy.
CBUS's Altman-Z score of -3.83 is in line compared to the rest of the industry. CBUS outperforms 45.55% of its industry peers.
CBUS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CBUS (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.83
ROIC/WACCN/A
WACC11.06%
CBUS Yearly LT Debt VS Equity VS FCFCBUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CBUS has a Current Ratio of 1.23. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
CBUS has a worse Current ratio (1.23) than 85.48% of its industry peers.
CBUS has a Quick Ratio of 1.23. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
CBUS has a Quick ratio of 1.23. This is amonst the worse of the industry: CBUS underperforms 84.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
CBUS Yearly Current Assets VS Current LiabilitesCBUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

CBUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.34%, which is quite impressive.
CBUS shows a strong growth in Revenue. In the last year, the Revenue has grown by 104.08%.
Measured over the past years, CBUS shows a very negative growth in Revenue. The Revenue has been decreasing by -10.20% on average per year.
EPS 1Y (TTM)85.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
Revenue 1Y (TTM)104.08%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%89.72%

3.2 Future

The Earnings Per Share is expected to grow by 20.85% on average over the next years. This is a very strong growth
Based on estimates for the next years, CBUS will show a very strong growth in Revenue. The Revenue will grow by 137.38% on average per year.
EPS Next Y4.15%
EPS Next 2Y18.65%
EPS Next 3Y9.85%
EPS Next 5Y20.85%
Revenue Next Year32.44%
Revenue Next 2Y50.46%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CBUS Yearly Revenue VS EstimatesCBUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CBUS Yearly EPS VS EstimatesCBUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBUS Price Earnings VS Forward Price EarningsCBUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBUS Per share dataCBUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.65%
EPS Next 3Y9.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CBUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIBUS INC

NASDAQ:CBUS (8/8/2025, 4:30:02 PM)

1.44

-0.04 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-14 2025-08-14/amc
Inst Owners24.56%
Inst Owner Change0.33%
Ins Owners8.71%
Ins Owner Change63.25%
Market Cap72.12M
Analysts80
Price Target16.7 (1059.72%)
Short Float %4.72%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.45%
Min EPS beat(2)-12.97%
Max EPS beat(2)-9.92%
EPS beat(4)1
Avg EPS beat(4)11.42%
Min EPS beat(4)-37.98%
Max EPS beat(4)106.57%
EPS beat(8)1
Avg EPS beat(8)-207.02%
EPS beat(12)4
Avg EPS beat(12)-134.41%
EPS beat(16)6
Avg EPS beat(16)-99.97%
Revenue beat(2)1
Avg Revenue beat(2)-2.99%
Min Revenue beat(2)-11.09%
Max Revenue beat(2)5.12%
Revenue beat(4)3
Avg Revenue beat(4)62.06%
Min Revenue beat(4)-11.09%
Max Revenue beat(4)167.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)19.38%
EPS NQ rev (3m)-3.48%
EPS NY rev (1m)4.89%
EPS NY rev (3m)-46.45%
Revenue NQ rev (1m)5.32%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)-1.31%
Revenue NY rev (3m)-36.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.18
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.09
BVpS1.4
TBVpS-3.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.03%
ROE -391.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13%
Cap/Sales 18.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -3.83
F-Score5
WACC11.06%
ROIC/WACCN/A
Cap/Depr(3y)67.73%
Cap/Depr(5y)64.06%
Cap/Sales(3y)402.26%
Cap/Sales(5y)243.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
EPS Next Y4.15%
EPS Next 2Y18.65%
EPS Next 3Y9.85%
EPS Next 5Y20.85%
Revenue 1Y (TTM)104.08%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%89.72%
Revenue Next Year32.44%
Revenue Next 2Y50.46%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%
EBIT growth 1Y5.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.08%
EBIT Next 3Y29.53%
EBIT Next 5Y22.72%
FCF growth 1Y-251.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-267.6%
OCF growth 3YN/A
OCF growth 5YN/A